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 Summary 
I. SUMMARY 
 
 
Persistent infection with the gastric bacterial pathogen Helicobacter pylori (H. pylori) 
causes gastritis and predisposes carriers to a high gastric cancer risk, but has also been 
linked to protection from allergic, chronic inflammatory and autoimmune diseases. The 
beneficial consequences of chronic H. pylori infection have been proposed to result from 
the pathogen’s immunomodulatory properties. We show here that H. pylori inhibits the 
LPS-induced maturation of dendritic cells (DCs) as assessed by CD80/CD86 
upregulation and IL-12 secretion, and re-programs DCs towards a tolerance-promoting, 
semi-mature state. DCs that have been exposed to H. pylori in vitro or in vivo fail to 
induce T cell effector functions, and instead efficiently induce FoxP3 expression and 
suppressive properties in naive T cells. The experimental depletion of DCs breaks H. 
pylori-specific tolerance and results in improved control of the infection, but also in more 
severe immunopathology. Low-dose LPS administration overrides the manipulation of 
DCs by H. pylori in vitro and in vivo. Moreover, DCs infiltrating the gastric mucosa of 
human H. pylori carriers retain a semi-mature CD80lowCD86low state. Mechanistically, the 
tolerogenic activity of H. pylori-experienced DCs is shown to require IL-18 in vitro and in 
vivo. DC-derived IL-18 directly acts on T cells to drive their conversion to regulatory T 
cells (Treg). Additionally, two bacterial factors, γ-glutamyl transpeptidase (GGT) and 
vacuolating cytotoxin (VacA) are shown to contribute critically to the tolerization of DCs 
by H. pylori. Isogenic mutants lacking GGT or VacA fail to drive DC tolerization and 
consequently, these DCs fail to drive FoxP3 expression in naive T cells. Both mutants 
fail to colonize mice at wild type levels, induce stronger Th1 and Th17 responses and/or 
trigger more severe gastric pathology.  
Moreover, CD4+CD25+ Tregs from infected wild type mice but not Il-18-/- or Il-18r-/- mice 
protect from clinical and histopathological manifestations in an experimental model of 
asthma. Additionally, asthma protection is lost, if the mice were infected with ΔvacA 
mutant prior to allergen challenge, underscoring the importance of this bacterial protein 
in skewing the immune system towards tolerance. 
Overall, our results indicate that tolerogenic re-programming of DCs ensures the 
persistence of H. pylori and protects against asthma in a process that requires IL-18 and 
the two bacterial factors GGT and VacA. 
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II. ZUSAMMENFASSUNG 
 
 
Eine persistente Infektion mit dem bakteriellen Magenpathogen Helicobacter pylori führt 
zu chronischer Gastritis und bringt ein erhöhtes Risiko an Magenkrebs zu erkranken mit 
sich. Allerdings wird angenommen, dass eine Infektion mit H. pylori nicht ausschliesslich 
negative Konsequenzen für seinen Träger hat, sondern auch gegen Allergien, 
chronische Entzündungen und Autoimmunerkrankungen schützen kann. Es wird 
vermutet, dass dieser Schutz durch die immunomodulatorischen Eigenschaften des 
Bakteriums hervorgerufen wird. 
Auf Grund von Expressionsanalysen von CD80/CD86 Oberflächenrezeptoren und der 
Sekretion des Zytokines IL-12, zeigen wir nun, dass H. pylori in der Lage ist die LPS-
induzierte Maturierung dendritischer Zellen zu inhibieren. Diese Inhibition führt zu einem 
halb-maturierten, tolerogenen Phänotyp und die betroffenen dendritischen Zellen sind 
einerseits nicht mehr in der Lage effiziente Effektor T-Zell Antworten zu vermitteln, 
andererseits induzieren sie die Expression des Transkriptionsfaktor FoxP3 in naiven T 
Zellen. Die experimentelle Depletierung dendritischer Zellen bricht die pathogen-
spezifische Toleranz des Wirtes und führt zu einer besseren Kontrolle der Infektion, 
allerdings auf Kosten einer erhöhten Immunopathologie im Magen. Zusätzlich konnten 
wir in der Magenmucosa von humanen Trägern phänotypisch ähnliche, sprich 
dendritische Zellen, die nur wenig CD80 und CD86 exprimieren, nachweisen. 
Mechanistisch konnten wir zeigen, dass die Sekretion von IL-18 durch diese tolerogenen 
dendritischen Zellen benötigt wird, um in naiven T Zellen die Expression von FoxP3 zu 
aktivieren. Des Weiteren  konnten wir die Notwendigkeit zweier bakterieller Faktoren, 
der γ-Glutamyl Transpeptidase (GGT) und des vakuolierenden Zytotoxins (VacA), für die 
Tolerisierung dendritischer Zellen nachweisen. Mutante Bakterienstämme, die kein GGT 
oder VacA produzieren, scheitern in der Tolerisierung dendritischer Zellen und als 
Konsequenz können diese keine regulatorischen T Zellen mehr induzieren. Beide 
Mutanten zeigen deutlich niedrigere Kolonnisierung im Magen eines Wirtes im Vergleich 
zu dem entsprechenden Wildtyp Stamm. Diese Reduzierung wird von stärkeren Th1 und 
Th17 Immunantworten und/oder erhöhter Magenpathologie begleitet. 
Wir konnten auch zeigen, dass zwar regulatorische T Zellen von infizierten Wildtyp 
Mäusen, jedoch nicht regulatorische T Zellen von Il-18-/- oder Il-18r-/- Tieren, die 
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klinische und histopathologische Manifestation von Asthma verhindern. Ein ähnlicher 
Verlust des Schutzes vor Asthma ist in Mäusen zu beobachten, die mit der ΔvacA 
Mutante infiziert wurden. Dies unterstreicht zusätzlich die Wichtigkeit von VacA bei der 
Induktion von H. pylori-spezifischer Immuntoleranz. 
Zusammenfassend deuten unsere Resultate darauf hin, dass die tolerogene 
Programmierung von dendritischen Zellen die Persistenz von H. pylori und den 
Asthmaschutz durch das Pathogen sichern und, dass der ganze Prozess abhängig von 
IL-18 und den bakteriellen Faktoren GGT und VacA ist.  
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Abbreviations 
III. ABBREVIATIONS 
 
 
AP1     Activator protein 1 
BabA     Antigen binding adhesin 
cagA     Cytotoxin-associated gene A 
cag-PAI    Cag pathogenicity island 
CD     Cluster of differentiation 
DAMP     Damage-associated molecular pattern 
DC     Dendritic cell 
GGT     γ-Glutymyl transpeptidase 
H. pylori    Helicobacter pylori 
HpaA     H. pylori adhesin A 
IFN-γ     Interferon-gamma 
IL-     Interleukin- 
LPS     Lipopolysaccharides 
MALT     Mucosa-associated lymphoid tissue 
MAPK     Mitogen-activated protein kinase 
MLN     Mesenteric lymph node 
NF-κB     nuclear factor 'kappa-light-chain-enhancer 
 of activated B-cells  
NLR     NOD-like receptor 
NOD     Nuleotide oligomerization domain 
PAMP     Pathogen-associated molecular pattern 
PRR     Pattern recognition receptor 
SabA     Sialic acid binding adhesin 
T4SS     Type IV secretion system 
Th     T helper 
TLR     Toll-like receptor 
TNF-α     Tumor necrosis factor-alpha 
Treg     T-regulatory cell 
VacA     Vacuolating cytotoxin 
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1.  INTRODUCTION 
 
 
1.1.1 HELICOBACTER PYLORI 
 
 
1.1.2 TAXONOMY 
 
When Marshall et al. successfully cultured a novel gastric bacterium from the antral 
biopsy from patients with gastritis and gastric ulcers in 1982, they classified it as a new 
species in the genus Campylobacter as Campylobacter pyloridis (later changed to 
Campylobacter pylori) (1). It was not before 1989 that an important stage in the 
development of the taxonomy of gastric microorganisms took place by creating a new 
genus called Helicobacter thereby transferring Campylobacter pylori to that genus (2, 3). 
 
Fig.1: Different morphology 
of Helicobacter spp. S-
shaped H. pylori with sheathed 
polar flagella (left) and spiral 
shaped H. felis with bipolar 
sheathed flagella (right). Field 
emission SEM. Courtesy of 
Lucy Thompson, University of  
              New South Wales. 
 
 
As mentioned above the first representative of the Helicobacter genus to be discovered 
was Helicobacter pylori (H. pylori), named after its primary biological niche, the pylorus 
of the human stomach. Subsequently, over 32 different species of Helicobacter have 
been isolated from several organisms, including cats, dogs, sheep, rodents, pigs, birds, 
cheethas, poultry and monkey (4).  Helicobacter spp. share some common features. They 
are gram-negative, microaerophilic bacteria possessing 4 up to 20 flagella, which make 
them highly motile, and they express high levels of urease, an enzyme which converts 
urea into carbonic acid and ammonia. They are s-shaped or curved (Fig. 1), and they 
have a G+C content of chromosomal DNA of 35-44 mol%. A distinctive attribute of 
Helicobacter spp. within the genus is their primary location in the host. Besides the 
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gastrointestinal tract, Helicobacter spp. have been isolated from the liver and recently 
from the pancreas, which was considered to be a sterile organ so far (5, 6). 
 
 
1.1.2 VIRULENCE FACTORS 
 
Bacterial virulence factors can be defined as traits or molecules that are necessary for 
pathogenesis, or at least, whose loss significantly reduces pathogenesis. Multiple of 
such factors have been proposed to contribute to H. pylori virulence. Among these are 
bacterial urease activity (7), falgellar motility (8), exotoxins (9), adhesion molecules (10), and 
others (11).  
All Helicobacter spp. exhibit modest to marked urease activity in vitro and in vivo thereby 
enabling the bacteria to colonize the acidic environment of the stomach by providing an 
alkaline microenvironment (12). Several studies support this assumption by showing that 
isogenic urease-negative strains are not able to colonize the stomach of gnotobiotic 
piglets, ferrets, and nude mice. Additionally, in contrast to their wild-type counterparts 
which induce gastritis after successfully colonizing their host stomach, urease-negative 
Helicobacter do not induce any signs of disease (13, 14).  
H. pylori is highly motile by means of flagellar propulsion. This motility is considered as 
an important virulence factor, enabling H. pylori to travel through the extreme acidic 
gastric lumen to reach the more neutral environment of the mucus layer (8). There is 
evidence that the degree of motility of H. pylori strains correlates with the degree of 
infectivity. Eaton et al. showed that the most motile strain was the most successful in 
terms of infection rate, while the least motile displayed only a weak rate of infection in 
the well-established gnotobiotic piglet model (15, 16). In the same model, H. pylori strains 
defective in the genes coding for the minor and major flagellar proteins, FlaB and FlaA 
respectively, and thus impaired in their motility, colonized the host but only persisted for 
2 days. In contrast, the wild-type strain colonized all piglets and persisted for at least ten 
days after inoculation (17), highlighting the importance of motility for the pathogen to 
successfully settle in the stomach of its host. 
Besides traits that enable H. pylori to adapt to the acidic environment of the gastric tract 
and to reach its main biological niche, the mucus layer, there are other factors 
contributing to the virulence of H. pylori. The most prominent among them is the 
Cytotoxin-associated gene A (CagA) protein. The cagA locus is always associated with a 
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40-kilobase fragment of DNA known as the cag pathogenicity island (cag-PAI) (18). The 
cagA protein is actively translocated from the bacterium to the host cells by a type IV 
secretion system (T4SS). Upon translocation, CagA gets phosphorylated inside the host 
cell (19, 20). Strikingly, biopsies from patients suffering from severe gastric diseases 
ranging from chronic active gastritis to mucosa-associated lymphoid tissue (MALT) 
lymphoma or gastric adenocarcinoma harbor the cagA gene in approximately 90% of all 
the cases, establishing a direct correlation of the presence of the cagA gene with 
disease (18). The effector functions of CagA are manifold. Morphological changes in 
epithelial cells by actin polymerization (21), promotion of inflammation (22-24), dysregulation 
of proliferation (25), and attenuation of T-cell apoptosis have been attributed to CagA 
translocation (26). 
Another wide-spread virulence factor among Helicobacter species is the exotoxin 
vacuolating cytotoxin VacA. This multifunctional cytotoxin intoxicates a variety of cell 
types, including epithelial cells and immune cells, resulting in an array of cellular 
responses. Among them we find induction of vacuolation (9), alteration in mitochondrial 
membrane permeability (27), inhibition of antigen presentation on B-lymphocytes (28), and 
inhibition of T-cell proliferation (29). Besides the effects on T- and B-lymphocytes 
described above, which might result in localized immunosuppression, VacA additionally 
induces pro-inflammatory effects by stimulating tumor necrosis factor- (TNF-)α- and 
interleukin- (IL-)6-secretion in mast cells (30). Thus, VacA earns its name as a 
multifunctional toxin by being both an immunosuppressor and an immunostimulant. 
Many H. pylori adhesins have been implicated to promote the bacterium`s virulence by 
enabling its adherence to gastric epithelial cells, thereby enhancing the activity of other 
bacterial molecules involved in virulence. This outer membrane family of proteins 
includes the blood group antigen binding adhesin (BabA), the sialic acid binding adhesin 
(SabA), which bind to Lewis b and sialyl Lewis x receptors, respectively, and the H. 
pylori adhesin A (HpaA) (31-34). 
γ-Glutamyl transpeptidase (GGT) has recently been added to the list of virulence factors 
associated with H. pylori. Kim et al. showed that GGT induces cell-cycle arrest at the G1 
to S phase transition in human T-cells (35). In addition, recombinant GGT leads to the 
generation of H2O2 in primary gastric epithelial and AGS cells, resulting in the activation 
of the NF-κB pathway and up-regulation of IL-8 (36). Most strikingly, H. pylori strains 
recovered from patients with peptic ulcer disease showed a significantly higher GGT 
activity than strains isolated from patients suffering from nonulcer dyspepsia (35, 36). The 
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high number of involved virulence factors, and the antigenic variation of the respective 
genes in different H. pylori strains, underlines the tremendous capacity of the bacteria to 
continuously adapt to their hostile environment (37). 
 
 
1.1.3 PREVALENCE AND TRANSMISSION 
 
H. pylori is one of the most widespread bacterial infections, affecting approximately 50% 
of the world`s population (38). The prevalence of H. pylori infection varies widely by 
geographic area, socioeconomic status, age, and ethnicity. Infection rates are higher in 
developing (≥ 70%) than in developed countries (≤ 40%) and seem to be inversely 
correlated with hygiene standards (39)(Fig. 2). Most infections are acqired during early 
childhood with a lifelong persistence if not treated (40, 41). Spontaneous clearance can 
occur, but is rare (0.2-1%/year). Humans appear to be the only reservoir of H. pylori, 
although several studies show a possible correlation of domestic animals (cats and 
sheep) harbouring the bacteria with a higher frequency of infection in the owners. 
Starting from humans as the reservoir, the most likely route of transmission is from 
person to person, by either the fecal-oral route or by the oral-oral route. Additionally, 
transmission via contaminated food or water is regarded as possible, although not 
convincingly proven (39). 
 
Fig. 2:  Prevalence of H. pylori in asymptomatic adults. Data are from population-based surveys of 
healthy adults. Adapted from (42). 
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1.2 HELICOBACTER PYLORI AND GASTRIC CANCER 
 
 
1.2.1 EPIDEMIOLOGY 
 
Besides the induction of gastritis, gastric ulcers, and duodenal ulcers, H. pylori infection 
can lead to the development of gastric adenocarcinomas and MALT lymphoma. 
Therefore, H. pylori was classified as a class I carcinogen by the World Health 
Organization in 1994 (43). Although the majority of infected individuals remain 
asymptomatic, despite a lifelong persistence of the infection, 1-2% of the carriers will 
eventually develop gastric adenocarcinoma (44) or MALT lymphoma (below 1%) (45).  
Although gastric cancer-related deaths are constantly decreasing since 1930 in 
industrialized countries, it is estimated that approximately 738`000 deaths occurred in 
2008, making this cancer one of the top two killers from cancer worldwide. One major 
determinant for the favorable negative trend is the reduction in chronic H. pylori 
infections in most parts of the world (46). Although a negative trend has to be appreciated, 
H. pylori infection-related diseases are still a considerable burden for the public health 
system. 
 
 
1.2.2 MECHANISMS OF CARCINOGENESIS 
 
In general, development of gastric cancer is a multistep process initially starting by 
diffuse infiltration of the gastric mucosa by lymphocytes after acquiring the infection. This 
so-called chronic active nonatrophic gastritis advances slowly to the multifocal atrophic 
type of gastritis, which is characterized by loss of glands (atrophy) at the antrum-corpus 
junction, followed by intestinal metaplasia. At this precancerous stage, the glands and 
the foveolar epithelium are replaced by "intestinal-like" cells. Subsequently, dilatation 
and branching of gastric glands and atypical morphology and sustained mitotic activity of 
epithelial cells can be observed. After acquiring this dysplastic stage, most of the 
affected patients will progress to early carcinomas and advanced, invasive 
adenocarcinoma, suggesting that genetic alterations have already taken place (47, 48)(Fig. 
3).  Gastric adenocarcinoma constitutes over 85% of all gastric malignancies. However, 
H. pylori can additionally cause MALT lymphoma of the stomach, which constitutes 
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roughly 3% of all gastric malignancies and 10% of all non-Hodgkin lymphomas (49, 50). 
Clinical, epidemiological, and experimental data have provided strong evidence for a 
causal involvement of H. pylori in the etiology of this malignancy (45).  
Although roughly 50% of the world population is infected with H. pylori, only a minority 
will develop gastric cancer, highlighting the importance of the combination of bacterial 
factors, environmental traits, and the host immune response in the progression toward 
malignant disease. Different virulence factors have been associated with a higher risk of 
gastric cancer. CagA+ strains in particular are more cancerogenic in humans and in 
animal models of disease (51, 52). Besides bacterial factors, the host immune response 
plays an important role in the development of malignant lesions. Polymorphisms in the 
genes for IL-1β, the IL-1β receptor, and IL-10 correlate with an increased risk of gastric 
cancer (52-54). Additionally, H. pylori infection leads to the induction of high levels of 
reactive oxygen species and enhanced epithelial cell proliferation  in the gastric tissue 
(55). More recently Toller et al. showed the induction of double strand breaks in epithelial 
 
 
Fig. 3:  Histological progression of Helicobacter-induced gastric cancer in a B6129 mouse model. 
Adapted from (56, 57) 
 
cells upon H. pylori exposure (58). In theory, these effects of H. pylori on the gastric tissue 
enhance the risk of acquiring genetic alterations and thus driving the development of 
cancerous lesions. The induction of genetic alterations by the pathogen suggests that 
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there is a "point of no return", and that disease progression in later stages is not 
exclusively depending on a persistent infection of the host with the microorganism (59). 
Support for this hypothesis comes from follow-up studies after eradication therapy of the 
bacteria. Regression has been observed upon eradication for acute, chronic and 
atrophic gastritis, but not for metaplastic and dysplastic lesions, suggesting that that 
persistent infection is not required for proceeding through the late disease stages of 
carcinogenesis (60, 61). 
 
 
1.2.3 HELICOBACTER PYLORI: FRIEND OR FOE? 
 
As discussed in the previous section, persistent infection with H. pylori causes gastritis 
and predisposes carriers to a high gastric cancer risk. Besides its pathological effects in 
the stomach, it is speculated that H. pylori is causally linked to a variety of extragastric 
diseases, some of which include functional dyspepsia (62), gastroesophageal reflux 
disease (63), cardiovascular diseases (64-66), iron deficiency anemia (67), idiopathic 
thrombotic purpura (68), and others (69).  
Considering the multiple pathological effects induced by H. pylori in its human host, we 
might argue that this microorganism should be eradicated by the wide-spread use of 
antibiotics or development of vaccines. On the other hand, only a minority of carriers is 
adversely affected by the infection and an indiscriminate use of antibiotics may lead to 
bacterial resistance. More importantly, there is growing evidence that H. pylori may 
prevent against asthma (70-73), allergies and other chronic inflammatory diseases (74). This 
inverse correlation is most evident in Western societies that have largely eliminated H. 
pylori (Fig. 2 and 4A) infections due to frequent use of antibiotics in childhood and better 
sanitary conditions. In these populations, the rates of such diseases have reached 
epidemic proportion, putting a huge burden on the public health system (75)(Fig. 4B). 
Therefore any decision on complete eradication of H. pylori might be premature and 
even detrimental, especially since Arnold et al. showed recently that neonatal infection 
with H. pylori protects mice against the clinical and histopathological symptoms of 
asthma (70). Understanding the mechanisms of H. pylori-mediated asthma protection 
would have a great impact on the decisions how to deal with this pathogen. 
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The innate immune response in the stomach is initiated upon binding of pathogen- or 
damage-associated molecular patterns (PAMPs/DAMPs) or to pattern recognition 
receptors (PRR) located at the cell surface, endosomal membranes and the cytosol. 
These receptors recognize several PAMPs such as flagellin, peptidoglycan, and 
lipopolysaccharide (LPS). Detailed studies on the role of various PRRs in the context of 
a H. pylori infection have been performed. Namely, the involvement of Toll-like receptors 
(TLRs), cytosolic nucleotide oligomerization domain (NOD)-like receptors (NLRs), C-type 
lectins and caspase-recruiting domain proteases have been under investigation. TLRs 
and NLRs are expressed by the first component of the innate immune system to be 
encountered by H. pylori, the epithelial cell lining of the gastric mucosa. Recognition of 
H. pylori by TLR-2 (77, 78) and NOD-1 (24, 79) results in the activation of MAPKs and the 
transcription factors NF-κB and AP-1 (24, 79) followed by subsequent secretion of various 
pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α, IL-8 and chemokines such as 
MCP-1, GRO-α, MIP-1α, and IL-8 in a T4SS-dependent manner (80-82). Whether the 
 
 
Fig. 4: The decline of H. pylori infection rates inversely correlates with an increase in asthma 
incidence. Prevalence of H. pylori in asymptomatic adults. Data are from population-based surveys of 
healthy adults (A). Worldwide asthma incidence (B). Figure adapted from (42, 76). 
 
 
1.3 IMMUNE RESPONSES TO HELICOBACTER PYLORI 
 
 
1.3.1 INNATE IMMUNITY 
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classical receptor for bacterial LPS, TLR-4 (78, 83, 84), and/or the classical receptor for 
bacterial flagellin TLR-5 (77, 78, 83-85) are required for this response by the gastric epithelium 
is still controversial. The local release of cytokines and chemokines by the epithelial cells 
of the gastric mucosa leads to the recruitment of various types of immune cells, including 
granulocytes, monocytes and lymphocytes. Neutrophils, a characteristic infiltrating cell 
type in H. pylori infections, upregulate IL-12, IL-23 and TNF-α via engagement of TLR-2 
and subsequent NF-κB activation upon contact with the pathogen (86). Similarly, H. pylori 
activates TLR-2 and TLR-4 on macrophages leading to the secretion of IL-12 and IL-10 
or L-6 and IL-1β, respectively (87). Interestingly, B-cells exposed to H. pylori extract 
produce large amounts of the regulatory cytokine IL10 in a TLR-2-/MyD-88-dependent 
manner. Additionally, they acquire the ability to efficiently induce IL-10 expression in co-
cultured, naive CD4+ T cells, thereby converting the T cells to T-regulatory-1 (Tr1)-like 
cells with suppressive activity (88). Several other studies focused on the role of dendritic 
cells (DCs) in the context of a H. pylori infection, since they represent a critical link 
between the innate and the adaptive immune response. DCs can penetrate the 
gastrointestinal epithelial barrier in vivo and both luminal and subepithelial interactions of 
H. pylori or bacterial products with DCs have been reported (89-91). However, data on the 
activation of DCs by H. pylori are controversial. Pulsing of human peripheral blood 
monocyte-derived DCs (PMDCs) with H. pylori ex vivo leads to the generation of IL-12 
and simultaneously IL-10 with subsequent induction of T helper (Th) 1 or Th2/regulatory 
T-cell (Treg) responses, respectively (92, 93). Yet another study co-cultured pulsed PMDCs 
with naive T-cells resulting in TNF-α, interferon-(IFN-) γ, and IL-2 secretion, indicative of 
a T-cell differentiation towards a Th1 phenotype (94) (Fig. 5). Geijtenbeek et al. showed 
that H. pylori-specific carbohydrate variants can bind to the C-type lectin DC-specific 
ICAM-3-grabbing nonintegrin (DC-SIGN/CD209) on human DCs resulting in enhanced 
expression of IL-10 but downregulation of IL-12 and IL-6 secretion, thus suppressing 
Th1 polarization in favour of persistence of the bacteria in the host (95, 96). The 
involvement of H. pylori-activated TLR signalling on human PMDC is not well 
characterized due to methodological limitations. It is believed that TLR-4 as well as TLR-
2 mediates the observed DC activation and cytokine secretion (95).  More data are 
available on the interaction of H. pylori with PRRs on murine DCs. Murine bone marrow-
derived DCs (BMDCs) phagocytose H. pylori resulting in the expression of pro-
inflammatory cytokines IL-1α, IL-1β, IL-6 and the anti-inflammatory cytokine IL-10 in a 
TLR-2-, TLR4-, and TLR9-dependent manner (97). However, only modest secretion of IL-
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12 is observed, resulting in diminished activation of splenocyte proliferation and INF-γ 
secretion compared with that induced by another pathogen that induces gastritis in mice, 
 
Fig. 5:  DCs are the critical link between 
innate and adaptive immune responses 
against H. pylori in the gastric mucosa. 
DCs penetrate the gastric epithelial lining 
and sample H. pylori antigens in the lumen. 
Activation of DCs by H. pylori antigens lead 
to the secretion of different cytokines, 
including IL-12, IL-23 and IL-10 and the 
induction of either Th1, Th2, Treg, or Th17 
responses.  The adaptive T cell responses 
are further amplified by the recruitment of 
polymorphonuclear cells and macrophages 
to the site of infection. From (56). 
 
 
 
 
 
 
 
Acinetobacter iwoffi. Additionally, the release of IL-12 upon stimulation of BMDC with 
Acinetobacter iwoffi is inhibited in the presence of H. pylori secreted factors (98). 
Recently, it has been shown that H. pylori-pulsed BMDCs enhance the production of IL-
23, promoting the proliferation of Th17 cells, a pathway that has been implicated, 
amongst others, in colitis, a disease sharing some mechanistical features with H. pylori 
induced gastritis (99, 100). Besides TLRs, the intracellular retinoic acid-inducible gene I 
(RIG-I) receptor interacts with H. pylori RNA resulting in the induction of type 1 
interferons. This response was independent of the known TLR adaptor proteins Myd88 
and TRIF (97). 
A third component of the DC activation program is composed of the NLRs NALP3 and 
NLRC4. Both of these intracellular signaling complexes are integral components of 
inflammasomes recognizing different PAMPs and DAMPs, including a variety of gram-
positive and gram-negative bacteria. This recognition leads to the activation of the 
cysteine protease caspase-1 and the subsequent proteolytical cleavage of pro-IL-1β and 
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pro-IL-18 into their mature, bio-active forms (101). Although stomach-specific 
overexpression of the pro-inflammatory cytokine IL-1β in mice leads to spontaneous 
gastric inflammation and cancer (54), the role of NALP3- and NLRC4-inflammasomes in 
the context of a H. pylori infection has not been addressed in detail yet. Further studies 
on the possible role of the highly dynamic NLR(s)-caspase-1-inflammasome(s) 
complex(es) in different cell types including epithelial cells, granulocytes and monocytes 
are needed. 
Taken together, much effort has been made to elucidate the role of innate immunity in H. 
pylori infections in vitro and in vivo, however, no clear trend can be established on 
whether the pathogen fully activates or evades the various components of the innate 
immune system.  
 
 
1.3.2 ADAPTIVE IMMUNITY 
 
Initially, it was believed that B-cell mediated humoral responses against H. pylori are 
decisive in the induction of protective immunity against the bacteria. Although H. pylori 
elicits antibody responses in the mucosa and the serum, it quickly became clear that the 
humoral arm of the immune system plays only a minor role in fighting the pathogen (102). 
To date, T cells are considered to be the main orchestrators of H. pylori-mediated 
adaptive immunity (102-104). Infiltrating T cells into the antrum of infected hosts mainly 
consist of CD4+ and CD8+ T cell subsets in mice and humans. Although both subsets 
show similar cytokine profiles, namely IFN-γ and TNF-α, upon activation by H. pylori-
specific antigens complexed to MHC class II molecules (105), no crucial role for CD8+ T 
cells has been shown, except in the absence of CD4+ T cells (106-108). The abundance of 
IFN-γ and TNF-α in the gastric mucosa of infected mice and humans clearly indicates a 
Th1 polarization, and especially IFN-γ expression is necessary to drive H. pylori-induced 
gastritis and pathology (104, 109). 
In contrast, a subset of individuals develops either a Th2 or a mixed Th1/Th2 profile in 
response to the infection. The secretion of IL-4 or both, IFN-γ and IL-4, respectively, has 
been suggested to protect from severe gastric pathology (110). It is generally believed that 
the Th1 cell subset protects the host against intracellular bacteria and the Th2 cell 
subset is crucial for immunity to parasites, the recently described Th17 cells are involved 
in the clearance of extracellular bacteria and thus very interesting in the context of a H. 
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pylori infection (111). Indeed, IL-17 secretion from tissue resident T cells, triggered by the 
release of IL-23 by DCs and macrophages, is detected at early and late stages of H. 
pylori infection (98, 112-114). The degree of inflammation and neutrophil infiltration is lower in 
IL-17 knock-out mice or upon IL-17 neutralization. Although the lack of IL-17 leads to 
decreased inflammation, the bacterial burden is higher in wild type mice as compared to 
knock-out mice, suggesting that IL-17 prevents inflammation-driven pathology but does 
not contribute to bacterial clearance (115, 116). Interestingly, Th17 and Th1 responses are 
suppressed in H. pylori-infected mice by a developmentally related population of CD4+ 
T-cells, namely peripheral induced FoxP3+ Tregs (117). The suppression of T-effector 
responses by Tregs in mice leads to the reduction of the degree of gastritis and to higher 
bacterial colonization levels, whereas depletion of Tregs reduced the bacterial burden 
and induced more severe gastritis and preneoplastic changes (118, 119). The key role of 
Tregs in the context of H. pylori infections is especially evident in the pediatric cohort. 
FoxP3+ cell numbers are higher, but IL-17 and IL-23 levels are lower in the gastric 
mucosa of infected children than in the mucosa of infected adults (120, 121). Additionally, 
Arnold et al. demonstrated that neonatally infected mice are highly colonized and 
protected against any signs of inflammation, gastritis or pre-cancerous changes. This 
neonatal tolerance is mediated by peripherally induced Tregs, which efficiently suppress 
Th1 and Th17 responses (122). The protective effect is lost upon depletion of CD25high 
Tregs (99, 123, 124). Moreover, in asymptomatic carriers of H. pylori, IL-10-expressing Tregs 
are particularly abundant in the mucosa compared with patients suffering from peptic 
ulcer disease (123, 125). High abundance of IL-10-expressing Tregs is directly correlated to 
high colonization scores and vice versa (126). This induction of Tregs by H. pylori, 
together with its weak immunogenicity, probably enables the bacteria to evade immune 
surveillance by dampening local adaptive immune responses. The mechanism of 
induction of such Tregs is not entirely clear. Better insights into this mechanism are 
crucial to overcome the tremendous obstacles encountered in the development of a 
potent, sterilizing vaccine. 
 
 
1.4 DENDRITIC CELLS AND IMMUNE TOLERANCE 
 
As disscussed in section 1.3.2 peripheral induced FoxP3+ Tregs promote persistent 
infection with H. pylori and prevent excessive immunopathology in the gastric epithelium 
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of the host (119, 122). In contrast to naturally occuring Tregs, which originate in the thymus, 
inducible Tregs are induced in peripheral tissues upon antigenic stimulation by DCs (127-
130). The cruical role of DCs in orchestrating innate and adaptive immunity is commonly 
recognized by workers in the field. DCs are a specialiced leukocyte cell type, that 
aquires, processes and present antigens to T cells. DCs have first been described as 
potent stimulators of adaptive immunity, but there is mounting evidence that these 
specialized antigen-presenting cells can additionally establish and maintain 
immunological tolerance (131).  
As mentioned above, tissue resident immature DCs constantly sample their environment 
for PAMPs and DAMPs. Upon sensing of such microbial and tissue damage signals via 
TLRs, NLRs, C-type lectins and others (132-134), DCs upregulate a variety of membrane 
receptors involved in antigen presentation and co-stimulation such as MHC-II, CD40, 
CD80, and CD86 as well as different cytokines that promote and modulate T cell 
polarization, such as IL-12, IL-6, IL-1β, IL-8 and IL-2 (92). Additionally, members of the 
NF-κB family are activated upon recognition of such PAMPs and DAMPs (135). 
Simultanously, DCs loose their capacity to sample antigens upon maturation but gain the 
capacity to migrate to the draining lymph nodes by the upregulation of homing receptors 
such as C-C chemokine receptor type 7 (CCR7) (92, 136). Now fully mature, DCs present 
three signals to circulating lymphocytes. Signal one is the presentation of the antigenic 
stimulus via MHC-II, signal two is provided by costimulatory molecules and signal three 
is provided by DC-derived cytokines (92, 137). The presentation of antigen with concomitant 
co-stimulation and cytokine secretion is needed to induce full-fledged effector T cells in 
the draining lymph nodes (134, 138, 139)(Fig. 6A). Whereas fully mature DCs possess 
primarily immunogenic functions, various phenotypes of tolerance-promoting DCs have 
been described. In particular, thymic plasmacytoid DCs promote the induction of natural 
FoxP3+ Tregs in the thymus to induce and maintain central suppressive tolerance (127, 
140). The signals provided by the thymic environment to render plamacytoid DCs 
tolerogenic are not completely understood, but probably involves thymic stromal 
lymphoietin secreted by Hassall`s corpuscles in the thymic medulla (141-143).  
Peripheral suppressive tolerance is mainly mediated by DCs within the mucosa and the 
lamina propria of different organs (e.g. lung, intestine, skin). For instance, intestinal DCs 
sample the lumen of the intestinal tract and migrate to the draining lymph nodes upon 
antigen uptake, where they induce FoxP3-expressing Tregs (144, 145). This tolerogenic 
capacity of intestinal DCs is belived to be induced by the mucosal environment of the 
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intestine, which is rich in TGF-β, retinoic acid, IL-10 and other anti-inflammatory, 
tolerance-promoting factors (146-149). Intestinal DCs believed to possess the most potent 
Treg inductive capacity express CD103, an integrin which is regulated by TGF-β 
signaling (150, 151).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: The maturation status of DCs influences T cell polarization: Presentation of an antigenic 
stimulus with concomitant co-stimulation via CD80/CD86 and secretion of IL-12 leads to Th1 polarization of 
naive T cells (A). Presentation of an antigen via MHC-II without concomitant co-stimulation and low 
secretion of pro-inflammatory cytokines preferentially induces FoxP3-expressing Tregs (B). Adapted from 
(152). 
 
Another key factor for the induction of Tregs is an environment containing little or no pro-
inflammatory cytokines, like IL-12 and IL-6, or co-stimulatory molecules such as CD40, 
CD80, and CD86 in combination with an antigenic stimulus (153). These circumstances 
are provided by so-called semi-mature DCs. Semi-mature DCs provide an antigenic 
stimulus by MHC-II presentation in the absence of co-stimulation and cytokine secretion 
to naive T cells, thereby promoting Treg differentiation (154-157) (Fig 6B).  
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Besides factors released by the local surroundings of tissue-resident DCs, a variety of 
other inputs have been implicated in the induction of tolerogenic DCs. Among them we 
find certain pathogens, which have evolved mechanisms that exploit Tregs to evade 
immune surveillance (158-160). For instance, helminths release factors that mimic 
immunosuppressive molecules like TGF-β, thereby promoting the induction of 
tolerogenic, Treg-inducing DCs (159). Many other microbial or viral factors and toxins have 
been shown to act similarly by prompting DCs to secrete anti-inflammatory cytokines, 
like IL-10 or TGF-β (161-164). Last but not least, Tregs, once established, have the capacity 
to render DCs tolerogenic by producing TGF-β and IL-10 (165). This mutual influence on 
each other leads to the induction of more Tregs, a mechanism sometimes referred to as 
"infectious tolerance".  
In summary, the instruction of DCs to become tolerogenic seems to be a result of a 
crosstalk between DCs and their local environment, already established Tregs and/or 
certain pathogens, mediated by different tolerance-promoting factors such as IL-10, 
TGF-β, retinoic acid and/or bacterial toxins. 
 
  Aims of the Study 
2. AIMS OF THE STUDY 
 
 
2.1  ELUCIDATING THE ROLE OF DENDRITIC CELLS IN HELICOBACTER 
PYLORI INFECTIONS 
 
DCs are considered as the critical link between innate and adaptive immunity. However, 
little effort has been made to elucidate the role of these professional antigen presenting 
cells in the context of a H. pylori infection in vivo. As discussed in section 1.3.1, the data 
gathered on the role of DCs are rather unclear. Some reports state that DCs primed with 
H. pylori induce fully-fletched Th1 polarized T cells, other results point into another 
direction by showing that H. pylori-experienced DCs induce Th2 polarized subsets of T 
cells. Additionally, some studies suggest that DCs can secrete IL-23 upon phagocytosis 
of the bacteria, subsequently inducing Th17 polarized T cells. Moreover, it is possible 
that the abundant Treg subset in the gastric mucosa of infected mice and humans can 
be induced by DCs. 
Surprisingly, most of the work was done in vitro using either human PMDCs or murine 
BMDCs, although mouse models and H. pylori strains, recapitulating the multistep 
process of cancer development, colonization behavior and host immune responses are 
available. Our group described the use of the H. pylori strain pre-mouse Sydney strain 1 
(PMSS1) to infect C57BL/6 mice as a suitable model to study H. pylori-host interactions 
and disease progression (122). Since PMSS1 readily colonizes C57BL/6 mice, a variety of 
DC-related knock-out strains in a C57BL/6 background are available for in vivo studies.  
Therefore we assessed the role of DCs in H. pylori PMSS1 infections using various 
mouse knock-out strains or the depletion of DCs in vivo, in addition to various in vitro 
assays, utilizing BMDCs. Additionally, we were interested in bacterial factors affecting 
DC activation and function. Therefore we assessed the impact of different H. pylori 
strains on DCs as compared to their parental, wild-typ strains. 
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3. RESULTS 
 
 
The results gathered during my PhD thesis are summarized by the following published 
articles.  
 
 
In the first article we show that H. pylori re-programs DCs toward a tolerogenic 
phenotype. H. pylori-experienced DCs efficiently induced CD25+FoxP3+ Tregs, while 
failing to induce robust T cell effector functions. Partial depletion of DCs in neonatal 
infected mice was sufficient to break H. pylori-specific tolerance and resulted in 
improved control of the infection, which was accompanied by increased T cell-driven 
immunopathology. The ability of H. pylori-experienced DCs to induce Tregs was 
dependent on DC-derived IL-18. Additionally, the protective effect of CD25+FoxP3+ 
Tregs from infected wild-type mice in an experimental model of asthma was lost if we 
used CD25+FoxP3+ Tregs from either IL-18-/- or IL-18r1-/- mice.  
 
 
In the second paper we highlight that the depletion of DCs during the challenge phase 
with H. pylori significantly improves vaccine-induced protective immunity. We link this 
observation to the capacity of H. pylori-experienced mesenteric lymph node (MLN) DCs 
to induce Tregs in vivo. The main purpose of the paper is to introduce the mycobacterial 
adjuvant CAF01 as possible candidate for human H. pylori vaccination. 
 
 
The third publication reviews how H. pylori manipulates innate and adaptive immunity of 
the host in order to establish persistent infection. We discuss several key components 
and signaling pathways of the immune system, which are preferentially targeted by the 
pathogen to evade immune surveillance and to reprogram it towards tolerance rather 
than immunity. 
 
 
Three publications are listed in the appendix since they either do not fit the scope of this 
thesis or are not yet published (but submitted). The first, submitted publication deals with 
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bacterial factors involved in tolerogenic re-programming of DCs and the consequences 
for persistent infection and immunopathology. Although placed in the appendix, most of 
the results are discussed in section 4. 
Two further publications to which I either share the first-authorship with Daniela B. 
Engler or to which I contributed are additionally presented in the appendix. They are not 
presented nor discussed in the result or discussion part, respectively, since both 
publications are outside of the main scope of this thesis. The first article addresses the 
role of microRNA-155 in the T cell-mediated control of H. pylori infections and the 
induction of colitis. The second publication deals with the T cell antigenicity of the H. 
pylori virulence factor CagA. 
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3.1 DC-DERIVED IL-18 DRIVES TREG DIFFERENTIATION, MURINE 
HELICOBACTER PYLORI-SPECIFIC IMMUNE TOLERANCE, AND ASTHMA 
PROTECTION 
 
 
Article published in Journal of Clinical Investigation, 2012 
 
Authors: Mathias Oertli, Malin Sundquist, Iris Hitzler, Daniela B. Engler, Isabelle Arnold, 
Sebastian Reuter, Joachim Maxeiner, Malin Hansson, Christian Taube, Marianne 
Quiding-Järbrink, and Anne Müller 
 
Contributions: I planned, conducted and analyzed the data summarized in figure 1-3, 5, 
7-8, and parts of figure 4. MS, MH and MQJ planned, conducted and analyzed the data 
summarized in figure 6. SR, JM and CT conducted and analyzed the data summarized 
in figure 4 and 9. DBE planned and conducted parts of the experiment summarized in 
figure 9. IH provided figure S3 A and B. AM suggested and planned experiments, helped 
with data analysis and wrote the manuscript  
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3.2 DENDRITIC CELLS PREVENT RATHER THAN PROMOTE IMMUNITY 
CONFERRED BY HELICOBACTER VACCINE USING A MYCOBACTERIAL 
ADJUVANT 
 
 
Article published in Gastroenterology, 2011 
  
Authors: Iris Hitzler, Mathias Oertli, Burkhard Becher, Else-Marie Agger and Anne 
Müller 
 
Contribution: IH designed and conducted most of the experiments and wrote the 
manuscript together with AM. I contributed figure 6E-F. BB and EMA provided helpful 
tools 
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3.3 H. PYLORI EXPLOITS AND MANIPULATES INNATE AND ADAPTIVE 
IMMUNE CELL SIGNALING PATHWAYS TO ESTABLISH PERSISTENCE 
INFECTION 
 
 
Published in Cell Communication and Signaling, 2011 
 
 
 Authors: Anne Müller, Mathias Oertli, and Isabelle Arnold 
 
Contributions: I and IA contributed the figures. AM wrote the manuscript 
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4. DISCUSSION 
 
 
4.1 HELICOBACTER PYLORI INFECTIONS INDUCE TOLEROGENIC RATHER 
THAN IMMUNOGENIC PROPERTIES IN DENDRITIC CELLS 
 
The gram-negative bacterial pathogen H. pylori colonizes the gastric mucosa of one half 
of the world population. The infection is acquired in early childhood and typically persists 
for life despite the fact that the infected host initiates a vigorous local and systemic 
immune response to the bacteria (126). Persistent colonization causes gastritis and 
predisposes infected individuals to gastric cancer (1, 45, 166, 167). Conversely, it is also 
linked to protection from allergic, chronic inflammatory and autoimmune diseases (70, 75, 
168). The majority of infected individuals remain asymptomatic, despite a lifelong 
persistence of the infection, implicating that H. pylori has developed mechanisms to 
evade immune surveillance and avoid immunopathology. 
We hypothesized that H. pylori resists immune surveillance by impairing DC function. 
Indeed, the exposure of BMDCs to live H. pylori has a profound impact on the properties 
of these cells in vitro. BMDCs experimentally infected with the pathogen express high 
levels of major histocompatibility complex (MHC) class II molecules, but surprisingly fail 
to up-regulate the co-stimulatory molecules cluster of differentiation (CD) 40, CD80 and 
CD86. Even the induced maturation of BMDCs with Escherichia coli (E. coli) 
lipopolysaccharide (LPS) is inhibited in the presence of live H. pylori. This inability of the 
bacteria to induce fully mature BMDCs and to inhibit LPS-provoked maturation is not 
only observed for the expression of co-stimulatory molecules, but is also evident for the 
production of pro-inflammatory cytokines such as IL-12p40 and IL-6. In contrast, 
exposure of BMDCs to H. pylori leads to the secretion of the anti-inflammatory cytokine 
IL-10. A similar pattern can be observed in human PMDCs. Low IL-12 and IL-6 secretion 
but enhanced expression of IL-10 is detected in H. pylori-experienced PMDCs and 
seems to depend on carbohydrate-specific signaling via the C-type lectin DC-SIGN (95, 
96). Interestingly, we could not attribute the effects of the bacteria on murine BMDCs 
expressing human DC-SIGN to to this C-type lectin.  
One might argue that the low antigenicity of H. pylori is the link to its weak effect on 
BMDC maturation. Various reports highlight the fact that H. pylori flagellin is a poor TLR5 
ligand, and the bacterium`s LPS consists predominantly of the biologically inactive tetra-
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acylated lipid A form (169, 170). On the other hand, the observation that H. pylori inhibits 
LPS-induced maturation of BMDCs suggests the involvement of a bacterial effector 
protein rather than only a passive effect due to few, if any, PAMPs. Support for this 
hypothesis comes from a recent study showing that the purified H. pylori effector protein 
VacA inhibits LPS-induced maturation of BMDCs as assessed by CD40, CD80, CD86 
and MHC-II upregulation and the secretion of IL-1β, IL-12p70, and TNF-α. 
Mechanistically, the authors show that VacA attenuates the LPS-induced down-
regulation of the transcription factor E2F1, a critical regulator of DC activation, resulting 
in inhibition of maturation (171). Nevertheless there might be a combinatorial effect of the 
weak immunogenicity of H. pylori and bacterial effector proteins responsible for the 
prevention of BMDC maturation.  
Most strikingly, the semi-mature phenotype (MHCIIhighCD80lowCD86lowCD40low) is not 
only observed for H. pylori-experienced murine BMDCs, but also in biopsies from 
infected patients. Although the frequency of DC-SIGN+CD11c+ DCs in the gastric 
mucosa of infected patients is significantly higher than that of their uninfected 
counterparts, no phenotypical differences in regard to the DC maturation state are 
observed. The DCs of infected as well as uninfected patients displayed high expression 
of HLA-DR but no or only little expression of the co-stimulatory molecules CD80, CD83, 
or CD86. Despite being present in large numbers in the mucosa of infected patients, the 
recruited DCs display a semi-mature phenotype, adding further support to the inability of 
H. pylori to fully activate DCs. 
In theory, DCs have to provide three signals in order to initiate fully-fledged effector T 
cells. The first signal is the antigenic trigger provided by MHC molecules presenting the 
cognate peptide, the second signal is provided by co-stimulatory molecules expressed at 
the surface such as CD40, CD80, CD83 and CD86 and the third signal are cytokines, 
secreted by either DCs or the microenvironment, that promote and modulate effector T 
cell functions (92, 137). Interestingly, DCs providing an antigenic stimulus by MHC 
molecules to T cells in the absence of concomitant upregulation of co-stimulatory 
molecules and/or the secretion of certain cytokines have been implicated in immune 
tolerance by promoting Treg differentiation (137, 154-157, 172). In H. pylori-experienced DCs, 
we miss two out of three signals, namely high levels of the proinflammatory cytokines IL-
12 and IL-6, and efficient up-regulation of the co-stimulatory membrane receptors CD40, 
CD80 and CD86. Based on these observations, we hypothesized that H. pylori renders 
DCs tolerogenic and that these DCs might be efficient inducers of Tregs. 
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4.2 HELICOBACTER PYLORI-EXPERIENCED DCS INDUCE TREGS RATHER 
THAN T-EFFECTOR RESPONSES 
 
Several studies report that the maturation status of DCs influences the modulation of 
effector T cell function. As discussed above, one of the inherent characteristics of DCs 
providing an antigenic stimulus while lacking co-stimulatory molecules and secretion of 
pro-inflammatory cytokines is their ability to convert naive T cells into FoxP3-expressing 
Tregs with a suppressive activity (155-157, 172). To test the assumption that H. pylori-
experienced, semi-mature BMDCs not only display a tolerogenic phenotype, but indeed 
are tolerance-promoting, we tested their ability to induce Tregs in vitro. In line with their 
semi-mature phenotype, H. pylori-treated BMDCs induce significantly more FoxP3+ 
Tregs compared to their untreated counterparts when cultured with naive T cells in the 
presence of anti-CD3 cross-linking antibody and recombinant TGF-β. In accordance with 
several studies, the addition of recombinant TGF-β to our co-culture system is necessary 
to induce and maintain FoxP3 expression (173, 174). Additionally, direct contact between H. 
pylori-experienced BMDCs and T cells is required for efficient induction of Tregs, as the 
separation of both cell populations by a trans-well filter abrogated the effect. One might 
argue that the artificial addition of recombinant TGF-β does not mirror a physiological, in 
vivo situation, but several studies report that the gastric mucosa of H. pylori-infected 
patients is a TGF-β-rich environment if compared to that of healthy individuals (175-178). In 
addition to be in a prerequisite for driving Treg induction, TGF-β is known to inhibit DC 
maturation and down-regulate IL-12 expression, rendering DCs tolerogenic (179, 180). It is 
tempting to speculate that this inhibitory effect of TGF-β on DCs might act synergistically 
with H. pylori to render gastric DCs tolerogenic in vivo. However it is not clear to what 
extent the tolerance-promoting capacity of H. pylori-experienced DCs relies on TGF- β in 
vivo. 
Since BMDCs are a rather artificial cell type which is not found in vivo, we 
immunomagnetically purified CD11c+ DCs from the mesenteric lymph nodes (MLNs) of 
uninfected C57BL/6 mice to further verify the tolerogenic capacity of H. pylori-
experienced DCs. MLNs represent one out of two reported sites of H. pylori-specific T 
cell priming alongside the Peyer`s patches (181-184). We next infected these MLN-derived 
DCs with live H. pylori prior to co-culture with naive T cells. Similar to their more artificial 
BMDC counterpart, H. pylori-treated MLN-derived DCs convert significantly more naive 
T cells to FoxP3+ Tregs as compared to untreated, control MLN DCs, indicating that the 
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tolerizing effects of H. pylori exposure are common to both BMDC and MLN DC 
populations. Interestingly, H. pylori-infected BMDCs and MLN DCs loaded with 
ovalbumin are able to trigger the conversion of naive ovalbumin-specific T cells to 
FoxP3+ Tregs in the absence of anti-CD3 cross-linking antibody, suggesting that the H. 
pylori-induced tolerogenic characteristics of DCs are not H. pylori-antigen-specific. The 
finding that H. pylori-experienced DCs are potent inducers of Tregs, are in accordance 
with a recent study by Robinson et al. (123). The authors report that asymptomatic carriers 
of H. pylori mount a Treg-predominant response to the bacterium, whereas carriers 
suffering from peptic ulcer disease exhibit strong Th1 and Th2 responses to the 
infection. In light of these findings we hypothesized that the exposure of DCs to H. pylori 
not only induces Tregs but simultaneously impairs their ability to activate potent T cell 
effector functions and the induction of Th1 differentiation. Indeed, BMDCs and MLN DCs 
infected with H. pylori are significantly less able than their naive counterparts to induce 
IFN-γ expression and secretion in OTII T cells activated by either anti-CD3 cross-linking 
or ovalbumin priming. The combined results suggest that exposure of DCs to the 
pathogen favours Treg over Th1 differentiation arguing, that strong gastric Treg 
responses induced by tolerogenic DCs ensure persistent infection in the host while 
preventing excessive immunopathology in vivo. 
Robinson et al. report that IL-10-expressing Tregs are particularly abundant in the 
gastric mucosa of asymptomatic carriers compared with patients with peptic ulcer 
disease. Interestingly, there is a strong association between mucosal IL-10 levels and 
bacterial densities. High Treg-derived IL-10 expression in the mucosa of asymptomatic 
carriers directly correlates with high colonization scores. In contrast, carriers suffering 
from peptic ulcer disease show low levels of mucosal IL-10 and a comparatively low 
bacterial burden. Additionally, Arnold et al. found that mice experimentally infected with 
H. pylori as adults have a relatively low bacterial burden but develop gastritis and gastric 
cancer precursor lesion, whereas mice infected with H. pylori during the neonatal period 
display a high bacterial colonization and no excessive immunopathology. Thus, H. pylori 
colonization levels and immunopathology are inversely correlated and are linked to 
drastic differences in local as well as systemic immune responses to the pathogen 
between the two groups, depending on the age and the time of infection. Whereas 
immunopathology and the decrease in colonization levels in mice infected as adults 
depends on Th1-differentiated CD4+IFN-y+ effector T cells, immunological tolerance 
developed by neonatally infected mice depends on peripherally induced Tregs (122, 185). 
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The neonatal infection model is therefore particularly interesting in the context of the 
ability of H. pylori to induce tolerogenic DCs in vivo. We therefore immunomagnetically 
isolated MLN DCs from either uninfected mice, mice infected as adults or mice infected 
during the neonatal period and compared their ability to convert naive T cells to FoxP3-
expressing Tregs.  MLN DCs from infected mice induce significantly more Tregs than 
their counterparts from uninfected mice. Interestingly, MLN DCs from neonatally 
infected, tolerant mice, which score highest in terms of colonization, are particularly good 
inducers of Tregs but fail to generate Th1 responses against the infection, whereas MLN 
DCs from adult-infected mice induce less Tregs but show an enhanced Th1 
differentiated phenotype. Data gathered in TCR-β-/- mice, which lack the α/β T cells 
altogether, suggest that the pronounced tolerogenic features of MLN DCs from mice 
infected as neonates is not simply a consequence of higher bacterial colonization levels 
but rather due to qualitative differences of these DCs compared to their counterparts 
from adult-infected mice. Neonatal and adult infection in the TCR-β-/- background results 
in similarly high bacterial burden in both age groups due to the complete absence of 
functional T cells (Fig. 7A). Surprisingly, MLN DCs from neonatally-infected TCR-β-/- 
knock-out mice still induce significantly more Tregs than MLN DCs of their adult-infected 
counterparts from the same knock-out (Fig. 7B), for reasons that remain unclear at the 
moment. 
 
 
Fig. 7: Adult and neonatal infection of TCR-β-/- mice. Colony forming units (CFU) of TCR-β-/- mice 
infected with H. pylori at 7 days (iN) or 6 weeks (iA) of age (A). Ability of MLN DCs isolated from A to 
convert naive T-cells to FoxP3+ Tregs (B). 
 
As mentioned above, the results strongly suggest that there is a difference in the quality 
of DCs isolated from neonatally infected mice compared to MLN DCs from their adult-
infected counterparts. In light of these findings comparative gene-expression arrays and 
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a closer analysis of the different DC sub-populations of the two age groups would be 
worthwhile. The experiment additionally allows us to answer the "chicken or the egg" 
question. Tregs and DCs can regulate one another in a negative feedback loop to 
promote and maintain a local and systemic tolerogenic, immunosuppressive 
environment. Several mechanisms how Tregs can induce tolerogenic DCs have been 
proposed. For instance, IL-10 secreted by Tregs (and other sources) can signal via the 
IL-10 receptor to maintain DCs in their immature state by repressing genes associated 
with DC maturation and immunogenicity (186, 187). Additionally, McGuirk et al. showed that 
Tregs can render DCs tolerogenic in an IL-10 dependent manner (165). As discussed 
above, Treg-derived TGF-β has similar effects on the maturation status and activation of 
DCs, although TGF-β signaling induces a much larger repertoire of genes in DCs than 
IL-10. Besides the induction of TGF-β itself as well as TGF-β receptor and others, the 
TGF-β-induced transcriptional program in DCs includes IL-18 (188-190). The crucial 
requirement for IL-18 for the function of tolerogenic DCs will be discussed later. In 
addition to the cytokine-induced inhibition of DC maturation, Tregs can form aggregates 
on DCs, thereby down-regulating their co-stimulatory molecules and maturation markers, 
thus impairing the ability of DCs to induce antigen-specific T cells (52). In summary, Tregs 
and DCs can mutually influence each other, raising the possibility that Tregs, once they 
are induced in the periphery by H. pylori, can render DCs tolerogenic independently of a 
previous DC-H. pylori interaction. Since we can exclude this mechanism in the TCR-β-/- 
background and the MLN DCs isolated from these mice still possess tolerance-
promoting features, we can propose that there is a Treg-independent mechanism in vivo 
rendering DCs tolerogenic, probably by a direct modulation of DCs by H. pylori.  In light 
of these findings, the TCR-β-/- knock-out provides a useful model to test factors (e.g. 
bacterial factors or pharmacological substances) modulating DC activity in the absence 
of adaptive immunity. Further support for the hypothesis that H. pylori-experienced DCs 
induce tolerance rather than promote immunity comes from several DC depletion studies 
in mice. Partial depletion of DCs in cd11cDTR-transgenic mice (which express the 
diphteria toxin receptor under the control of the DC-specific cd11c promotor) infected as 
adults with the highly virulent H. pylori strain PMSS1 results in lower colonization levels 
and enhanced gastric infiltration of CD4+ T cells compared to non-depleted controls (Fig. 
8A and B). Additionally, partial DC depletion in a vaccination model of H. pylori sonicate-
immunized mice improves protective immunity. DC-depleted, immunized mice show a 
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reduced bacterial burden accompanied by a generally stronger infiltration of immune 
cells into the gastric mucosa compared to non-depleted, immunized mice. Knowing that 
 
 
 
 
 
 
 
 
 
 
Fig. 8: DC depletion in adult infected mice. Colony forming units (CFU) of C57BL/6 (wt+DT) and cd11c-
DTR transgenic (tg+DT) mice (A). Gastric CD4+ T cell infiltration of mice shown in A (B). From 
supplementary figure 6 of section 3.2. 
 
the partial depletion of DCs amplifies T effector over T regulatory responses in adult-
infected mice and mice immunized prior to H. pylori challenge, we speculated that DCs 
are required for the development and maintenance of neonatally acquired immunological 
tolerance as well. Indeed, neonatally infected mice are colonized at significantly lower 
levels and exhibit higher levels of leukocyte and CD4+ T cell infiltration into their gastric 
mucosa upon DC-depletion than their DC-replete, infected and uninfected littermates. 
Although the depletion of CD11c+ DCs breaks neonatal tolerance to some extent, the 
reduction in the bacterial burden and the paralleled amplification of leukocyte and CD4+ 
T-cell infiltration is rather modest. We might argue that a complete depletion (rather than 
50% incomplete) of DCs over a longer period would lead to a complete protection of the 
host against the pathogen, as the remaining DCs can still promote tolerance. 
Additionally, an extended total DC depletion would be necessary to prevent the 
regeneration of newly induced peripheral Tregs, thereby disrupting the mutual induction 
of tolerogenic DCs and/or Tregs, respectively. In summary, DCs from infected mice 
promote Treg over T effector responses and DC-depletion in the cd11c-DTR transgenic 
model reveals that the maintenance of H. pylori-specific immune tolerance requires DCs, 
indicating that H. pylori-specific tolerogenic mechanisms are mediated by this cell type in 
vivo. In the face of these findings it becomes clear, that although much effort was put 
into the development of a sterilizing vaccine against the pathogen, hardly any treatment 
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regime was ever successful. We therefore postulate that in order to develop a protective 
vaccine against H. pylori, we have to overcome DC- and Treg-mediated tolerance 
counteracting host immunity to the bacterium. 
 
 
4.3 HOST REQUIREMENTS FOR H. PYLORI-SPECIFIC TOLERANCE 
 
 
4.3.1 IL-10 AND TGF-β ARE CRUCIAL FOR H. PYLORI-SPECIFIC IMMUNE 
TOLERANCE 
 
Various recent reports show that Tregs and DCs with tolerogenic capacity are necessary 
for mediating immune tolerance towards H. pylori, thereby enabling the pathogen to 
colonize its host persistently, both in human carriers and in experimentally infected 
animals (117, 121, 123). Several host factors have been proposed to be crucial to establish 
and maintain this state of tolerance. As mentioned above, Robinson et al. observed that 
patients suffering from peptic ulcer disease exhibited strong Th1 and Th2 responses to 
the pathogen, whereas asymptomatic carriers predominantly mounted a Treg-biased 
response. The Tregs in the healthy gastric mucosa of asymptomatic patients expressed 
high levels of IL-10 and received the highest colonization scores. Conversely, peptic 
ulcer disease patients expressed low levels of Treg-derived IL-10, receiving low scores 
for bacterial colonization (123). Additional support for the necessity of IL-10 to promote H. 
pylori persistence on the one hand, and in mediating H. pylori-induced 
immunomodulation on the other hand comes from a study conducted by Harris et al., 
and from experimental infections of IL-10-/- mice. Harris et al. found an inverse 
correlation between gastric mucosal regulatory cytokine levels and the severity of 
gastritis. Whereas children which typically exhibit only mild forms of gastritis showed 
high levels of gastric mucosal Treg numbers together with high levels of the anti-
inflammatory cytokines IL-10 and TGF-β, adults with more severe gastritis exhibited low 
Treg and low regulatory cytokine levels (121). Furthermore, IL-10-/- mice experimentally 
infected with H. pylori are able to spontaneously clear the infection. Not surprisingly, this 
clearance is accompanied by strongly enhanced Th1-mediated gastritis (191). Last but not 
least, polymorphisms in the IL-10 gene locus have been linked to an increased risk of 
gastritis and the development of gastric cancer. It is suggested that some polymorphism 
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of the IL-10 gene locus have a lower IL-10 production and thus increase susceptibility to 
the disease (192-195). Several possible sources of IL-10 in vivo and/or in vitro upon H. 
pylori infections have been proposed. Among them we find gastric mucosal-associated 
macrophages, DCs and Tregs (87, 95, 96, 118). In our hands DC-derived IL-10 is not needed 
to drive differentiation of naive T-cell towards Tregs in vitro, since BMDC from IL-10-/- 
donors are perfectly capable inducing FoxP3 expression. This might not be the case in 
vivo or alternatively, IL-10 is rather crucial for the maintenance of H. pylori-specific 
tolerance once it is established. H. pylori-specific tolerance can be maintained by either 
inhibiting pathogenic T cell responses and/or by rendering bystander DCs tolerogenic 
(see section 4.2).  
Another critical cytokine in the induction of Tregs via H. pylori-experienced DCs to 
establish immune tolerance is TGF-β. Several studies show that high levels of gastric 
and systemic TGF-β levels correlate with enhanced Treg responses, high colonization 
burden, and reduced gastric pathology in vivo (121, 176). This correlation is especially 
evident in the pediatric cohort. Interestingly, Serrano et al. provide additional evidence 
for a participation of TGF-β in the inverse relationship between H. pylori infection and the 
clinical expression of allergy markers in children (121, 176, 196). Further, we and others show 
that H. pylori-experienced DCs efficiently induce FoxP3 expression in co-cultured naive 
T cells in a TGF-β-dependent manner (117). Nevertheless, the main source of TGF-β in 
vivo seems to be gastric epithelial cells and once established Tregs, rather than DCs (175, 
197). Besides having anti-inflammatory capacity by either diminishing Th1 or Th2 
responses, TGF-β additionally has a profound impact on Th17 polarisation and on the 
activation/maturation of DCs (179, 180, 188, 198, 199). As discussed above, TGF-β can inhibit 
the maturation of DCs, thereby rendering them tolerogenic. Simultaneously, TGF-β 
signaling on DCs leads to the expression of IL-18 and is required for the development of 
Th17 cells (200). In summary, several lines of evidence indicate that IL-10 and TGF-β are 
crucial on the host side to maintain H. pylori-specific tolerance and to prevent T cell-
driven gastric immunopathology. 
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4.3.2 DC-DERIVED IL-18 DRIVES TREG DIFFERENTIATION, MURINE H.  PYLORI-
SPECIFIC IMMUNE TOLERANCE AND ASTHMA PROTECTION 
 
As discussed above, TGF-β signaling on DCs leads to the expression of IL-18. IL-18 is 
secreted upon treatment of DCs with H. pylori. Interestingly, neither IL-18-/- nor IL-18R-/- 
mice neonatally infected with H. pylori develop full tolerance upon infection. Similar, IL-
18-/- mice infected as adults are less densely colonized, but displayed enhanced gastric 
immunopathology after 1 month of infection with either H. pylori or H. felis as compared 
to their wild-type counterparts. In both the neonatal and the adult model of infection, the 
lack of IL-18 signaling negatively influences Treg numbers and enhances IL-17 
expression, but does not influence IFN-γ production in the MLNs. Moreover, in contrast 
to adoptive transferred CD4+CD25+ cells from neonatally infected wild-type mice, the 
same cell subset from IL-18-/- or IL-18R-/-mice does not confer asthma protection in a 
model of allergen-induced airway hyper-responsiveness. The reduced numbers of Tregs 
but enhanced Th17 polarization can be linked to DC-derived IL-18 as IL-18-/- DCs lose 
their tolerogenic features but induce robust Th17 responses in naive T cells upon H. 
pylori infection in vitro and in vivo. Thus, DC-derived IL-18 seems to be critical in 
skewing T cell differentiation away from Th17 cells and towards Tregs. Interestingly, the 
adoptive transfer of the same numbers of either wild type or IL-18-/- CD4+CD25+ cells in 
the asthma model suggests that IL-18 is not only critical to balance the Treg/Th17 ratio, 
but also for proper suppressive function of Tregs. Since Treg and Th17 cells are 
developmentally closely linked, the availability of IL-18 might either directly, by binding to 
its cognate receptor on T cells, or indirectly by its strong potential to induce IFN-γ 
expression, inhibit Th17 development, thereby shifting the immunological balance from 
Th17 towards Treg responses (198, 200-202). Counteracting the IL-18-dependent induction of 
Treg rather than Th17 responses from a common precursor is IL-1β. IL-1β can either 
convert Tregs into Th17 or directly induces Th17 cells from IL17R-expressing T cells (200, 
203-205). Surprisingly, both IL-18 and IL-1β are auto-catalytically cleaved by the same 
cysteine protease, caspase-1, to generate the mature, bio-active cytokines (101, 206).  
In summary, IL-18 signaling is critical for DC-induced Treg skewing and Th17 
suppression in mice. Additionally, IL-18 is crucial for a proper suppressive function of 
Tregs.  
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4.3.3 CASPASE-1 HAS BOTH PROINFLAMMATORY AND REGULATORY 
PROPERTIES IN H. PYLORI INFECTIONS 
 
Caspase-1 is activated upon the NLR-induced assembly of multiprotein complexes 
called inflammasomes and is critical for the recognition of numerous gram-negative and 
gram-positive bacteria (207-210). We showed recently that caspase-1 activation and 
subsequent release of mature IL-18 and IL-1β is induced in DCs upon H. pylori infection 
in vitro and both cytokines show elevated secretion levels in the gastric mucosa of 
infected mice (211). Interestingly, caspase-1-/- mice controlled the experimental infection 
with H. pylori more efficiently than their wild type counterparts, being less colonized but 
displaying increased levels of gastric IL-17, basically phenocopying the disease 
parameters of experimentally infected IL-18-/- mice. To further elucidate the dependence 
of the immunoregulatory and/or proinflammatory activities of caspase-1 on IL-18 and IL-
1β, we investigated the phenotypes of genetically modified mouse strains lacking either 
IL-18 or IL-1R infected with H. pylori. As discussed above, IL-18-/- mice are less densely 
colonized, suffer from enhanced gastric immunopathology, and show elevated levels of 
gastric IL-17 expression as compared to wild-type mice upon infection. In contrast, IL-
1R-/- mice experimentally infected with the pathogen display exactly the opposite 
phenotype. IL-1R-/- are clearly protected against gastritis and gastric preneoplasia that 
normally arises in wild type mice. The resistance of the IL-1R-/- strain to gastric 
immunopathology correlated with a high bacterial burden (significantly higher than in wild 
type mice) and with low gastric expression of IL-17 and IFN-γ (211). In summary, the 
results strongly imply that caspase-1 has both proinflammatory and regulatory activities, 
depending differentially on its two alternative substrates. Whereas the regulatory arm 
depends on IL-18 mediated suppression of Th17 responses and induction of Tregs, the 
proinflammatory arm depends on IL-1 signaling, and the differentiation of Th1 and Th17 
cell subsets. Which NLRs are involved in the recognition of H. pylori leading to caspase-
1 activation and IL-1β/IL-18 processing remains to be determined. In this context, it is 
interesting to note, that H. pylori lacks potent TLR ligands whereas the induction of IL-1β 
expression is MyD88-dependent (205). This raises the possibility that in the absence of 
pro-inflammatory TLR-signaling in conjunction with inflammasome activation via NLRs 
the processing of pre-IL1β and pre-IL-18 is biased towards the latter favouring Treg over 
Th17 differentiation during H. pylori infection. Support for this hypothesis comes from our 
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recent findings that the addition of E. coli LPS can reverse the tolerogenic effect of H. 
pylori on DCs. Since LPS is a strong inducer of IL-1β, which in turn is required for Th17  
 
 
 
Fig. 9: FoxP3 expression in naive T cells induced by H. pylori-experienced DCs can be broken by 
LPS administration. Capacity of H. pylori-experienced BMDC to induce FoxP3 expression in naive T cells 
in the presence of different LPS concentrations (A). Colony forming units (CFU) after administration of 1μg/g 
bodyweight LPS to neonatal-infected mice (B). Infiltrating IL-17+ T cells into the gastric mucosa of mice 
shown in B (C). 
 
polarization, the addition of LPS to DCs overrules the tolerizing effects of H. pylori, 
thereby abrogating their capacity to drive FoxP3+ expression in naive T cells (Fig. 9A). 
Strikingly, intraperitoneal administration of 20 μg/g bodyweight LPS to mice, with pre-
established robust neonatal tolerance against the pathogen, is sufficient to reduce 
bacterial colonization levels in the stomach. Concomitantly, higher percentages of 
infiltrating IL-17+ T cells into the gastric mucosa of LPS-treated mice are observed as 
compared to their untreated, infected littermates (Fig. 9B and C), again suggesting that a 
potent activation of TLR-/Myd88- and NF-κB-dependent expression of IL-1β can 
influence the relative availability of IL-1β and IL-18, thus dictating whether Tregs or Th17 
cells are preferentially induced (Fig 10). In vivo, due to the inability of H. pylori to 
efficiently activate TLR-mediated transcription, IL-1β is not available for caspase-1-
mediated processing, whereas IL-18 is produced in copious amounts due to efficient 
inflammasome activation, leading to the preferential induction of Tregs as opposed to 
Th17 cell subsets. Interestingly, several diallelic polymorphisms have been reported for 
the IL-1B gene encoding for IL-1β. Some of these polymorphisms have been linked to 
  Discussion 
  83
higher IL-1β production and were associated with an increased risk of gastric cancer and 
its precursor lesions (53, 212-214). The gastric cancer  
 
 
Fig. 10: Overview of the H. pylori/DC interaction and the subsequent instruction of naive T cells. 
Exposure of DCs with H. pylori leads to high expression of MHC class II, but only moderate expression of 
the co-stimulatory molecules CD80, CD86, and CD40, as well as low secretion of the cytokine IL-12. In 
contrast, copious amounts of IL-10 are made by H. pylori-experienced DCs. Recognition of H. pylori leads to 
inflammasome activation through an as yet undetermined NLR(s) resulting in caspase-1 activation and the 
processing and secretion of large quantities of IL-18 but only modest amounts of IL-1β due to H. pylori 
possessing only  weak TLR ligands. H. pylori-experienced DCs induce FoxP3+ Tregs in a TGF-β-, IL-18-, 
and possibly IL-10-dependent manner. In contrast, H. pylori-experienced DCs are weak inducers of Th17 
and Th1 cell subsets, thereby shifting the balance from Th1/Th17 to Tregs. Figure from (215). 
 
risk is even enhanced in individuals carrying these polymorphisms by H. pylori 
infections, supporting the assumption that excessive production of IL-1β shifts the 
balance from H. pylori-specific tolerance towards Th1-/Th17-driven gastric 
immunopathology. Based on our data we might assume that infected patients 
overexpressing IL-1β display lower Treg counts in the gastric mucosa and the draining 
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lymph nodes. Unfortunately, no data on this correlation are available yet. In summary, H. 
pylori-experienced DCs induce FoxP3+ Tregs in a TGF-β-, IL-18-, and probably IL-10-
dependent manner. H. pylori recognition leads to inflammasome activation triggering 
caspase-1-dependent processing of pre-IL-1β and pre-IL18. The relative availability of 
IL-1β and IL-18 dictates whether Th1/Th17 (high IL-1β, low IL-18) or Treg (low IL-1β, 
high IL-18) responses are preferentially induced.  
 
 
4.4 BACTERIAL FACTORS IN DC-MEDIATED TOLERANCE 
 
The observation that H. pylori suppresses LPS-induced maturation of BMDCs led us to 
the hypothesis that the observed semi-mature DC phenotype and their capability to drive 
FoxP3 expression in naive T cells are not exclusively a consequence of the weak 
immunogenicity of H. pylori but that additional bacterial factor(s) are crucially involved in 
the instruction of BMDCs to become tolerance-promoting. As discussed above, one 
promising candidate is VacA due its ability to inhibit LPS induced maturation of BMDCs 
(171). Additionally, isogenic vacA mutants are severely defective in their ability to establish 
infection and to persistently colonize their host in a mouse model of infection (216). 
Similarly, the secreted peptidase γ-glutamyl transpeptidase (GGT) has been shown to 
contribute to the ability of H. pylori to colonize the gastric mucosa and establish 
persistent infection of experimentally infected mice (217). First we compared isogenic 
ΔvacA and Δggt mutants with the wild type PMSS1 strain with respect to their ability to 
induce semi-mature BMDCs and their potential to inhibit LPS-induced maturation of 
BMDCs. Interestingly, BMDCs exposed to the isogenic mutants in different H. pylori 
backgrounds (PMSS1, P12, and G27) expressed similar levels of MHC-II, but 
significantly higher levels of CD80 than DCs exposed to the corresponding wild type 
bacteria. Most striking was the observation that the VacA- and GGT-deficient mutants 
failed to actively suppress the LPS-induced maturation of BMDCs as determined by 
CD80 expression and secreted IL-12p40 (Fig 11A-B). A possible functional contribution 
of both factors to H. pylori induced DC tolerogenicity was evident in the DC-T cell co-
culture system since both mutants exhibited a significant defect in generating DCs with 
tolerogenic activity (Fig 11C). Furthermore, both the ΔvacA and Δggt mutants showed 
significant defects in colonizing mice relative to the parental PMSS1 wild type strain after 
1 and 2 months of infection as adults (Fig 12A). Interestingly, the lower bacterial burden 
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of the two mutants was accompanied by stronger Th1 and Th17 responses in the 
mesenteric lymph nodes of the mutant-infected mice relative to animals infected with the  
 
 
Fig. 11: Inhibition of BMDC maturation and tolerogenic re-programming by H. pylori depends on the 
virulence factors VacA and GGT. BMDCs were infected with either H. pylori wild type (wt) or isogenic 
mutants lacking the virulence factors VacA (ΔvacA) or GGT (Δggt). Flow cytometric analysis of CD80 
expression (A). Quantification of IL-12p40 secretion as assessed by ELISA (B). Capacity of infected BMDCs 
to drive FoxP3 expression in naive T cells (C).  
 
parental wild type strain (see appendix 7.1), suggesting that both mutants elicited more 
articulated pathogen-specific T-cell responses. With the decreased capacity of both 
mutants for the tolerogenic re-programming in vitro in mind, we assessed whether the 
three different strains differentially affected DC tolerogenicity in vivo. Indeed, DCs 
immunomagnetically isolated from single cell MLN preparations from wild type-infected 
mice exhibited strong tolerogenic activity, whereas efficient induction of FoxP3 and 
CD25 expression in co-cultured naive T-cells was not observed with DCs from either 
uninfected controls or with DCs from mice infected with the ΔvacA and Δggt mutants 
after 1 month of infection (Fig 12B). At the later the point (2 months post infection), 
seven out of ten Δggt-infected animals had cleared the infection, and the ΔvacA-infected 
mice still exhibited lower colonization levels than the wild type-infected counterparts. The 
lower bacterial burden in ΔvacA-infected mice was accompanied by severe inflammation 
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and strongly aggravated preneoplastic lesions as compared to controls infected with the 
parental wild type strain, whereas Δggt-infected mice (most of which had cleared the 
infection) exhibited only mild, remaining inflammatory infiltrates  (Fig 12C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12: Efficient gastric colonization by H. pylori and tolerogenic re-programming of DCs in vivo 
requires VacA and GGT. Gastric bacterial colonization after 1 month (1M) and 2 months (2M) of adult 
infection with either wild type H. pylori (wt) or the isogenic Δggt and ΔvacA mutants (A). Capacity of MLN 
DCs of uninfected (ctrl) and 1 month infected (wt, Δggt and ΔvacA) mice to induce FoxP3 and CD25 
expression in naive T-cells (B). Pathology scores of mice shown in A, 2 months time point (C). 
 
The defect of the Δggt mutant in vitro and in vivo to tolerize DCs was phenocopied by 
pharmacological inhibition of its enzymatic activity, suggesting that the transpeptidase 
activity of GGT is required for its immunomodulatory effects (see appendix 7.1). In 
conclusion, both VacA and GGT contribute to DC tolerization in vitro and in vivo, and it is 
tempting to speculate that this mechanism consequently leads to the more efficient 
clearance of the mutant bacteria relative to the wild type strain. 
Our in vivo data are in line with the observation that VacA is not absolutely required for 
colonization, but VacA-proficiency does improve the process (216). However, 
epidemiological data suggest that strains expressing high levels of VacA correlate with 
more severe disease, contradicting our results (217). Additionally, VacA has been shown 
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to induce cell death via the disruption of mitochondrial membranes (218, 219). This induction 
of cell death in gastric epithelial cell is beneficial for H. pylori as it releases nutrients, but 
a possible effect on gastric DCs would be detrimental in terms of tolerogenic re-
programming. The discrepancy might be explained by different VacA concentrations or 
different VacA variants (toxic s1m1 versus non-toxic s2m2 variants), leading to different 
disease outcomes. While low VacA concentrations could be beneficial for the bacteria by 
tolerogenic re-programming of DCs and facilitated access to nutrients, large quantities of 
VacA could induce a pathogenic state by means of enhanced cell death, especially if the 
affected cell type is not only the gastric epithelial lining but additionally affects gastric 
"tolerogenic" DCs.  Additionally, VacA has been identified as a key factor in the H. pylori-
mediated inhibition of human T-cells (29, 30, 220) in vitro. VacA interferes with the IL-2 
receptor signaling pathway at the level of the Ca2+-calmodulin-dependent phosphatase 
calcineurin, thereby inhibiting T cell proliferation. As a consequence, the nuclear 
translocation of the transcription factor nuclear factor of activated T-cells (NFAT) is 
blocked, resulting in down-regulation of IL-2 gene transcription.  
Similarly, Gerhard et al. provided evidence for a complementary mechanism for the 
inhibition of human T-cell proliferation. The authors demonstrated that H. pylori GGT 
arrests antigen-activated T-cells in the G1 phase of the cell cycle by interfering with G1 
cyclin-dependent kinase activity. Deletion of the ggt gene abrogated the inhibitory effect 
of the bacteria on T-cell proliferation (221, 222). Moreover, it has been known that GGT 
contributes critically to gastric colonization of mice (223). The effects of VacA and GGT 
overlap in the inhibition of human T-cell proliferation in vitro, although these effects have 
not been shown yet to be relevant in murine models of infection. The more pronounced 
Th1-/Th17-responses, accompanied by similar (Δggt-infected mice) or more severe 
(ΔvacA-infected mice) immunopathology, observed after 2 months of infection with the 
isogenic mutant strains compared to wild type-infected mice, suggest that the described 
effects of both proteins on T-cell proliferation is not critical in vivo. Nevertheless, we 
tested the effect of the ΔvacA and Δggt strains on the tolerization of MLN DCs in the T 
cell-deficient TCR-β-/- background. As mentioned above, the tolerance promoting effects 
of VacA- and GGT-proficient H. pylori on DCs in the TCR-β-/- background were similar as 
in wild type mice. Interestingly, the ΔvacA mutant exhibited similar colonization levels 
(Fig 13A) in this set-up of neonatal infection, but the DCs of the ΔvacA-infected mice 
showed a clear deficiency in their ability to drive FoxP3 and CD25 expression in naive T-
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cells in our co-culture system (Fig 13B). Surprisingly, although adult-infected animals 
initially  
 
 
 
 
 
 
 
 
 
 
Fig. 13: The deficiency of the ΔvacA mutant in the re-programming of DCs is independent of T-cells 
in neonatal infection of TCR-β-/- mice. Colony forming units (CFU) of TCR-β-/- mice infected with H. pylori 
at 7 days (iN) or 6 weeks (iA) of age with either VacA-proficient (wt) or VacA-deficient (ΔvacA) H. pylori (A). 
Ability of MLN DCs isolated from A to convert naive T-cells to FoxP3+ Tregs (B). 
 
support colonization by the Δggt mutant, no Δggt-deficient bacteria could ever be 
retrieved from neonatally infected mice, independent of the T-cell proficiency of the host 
(data not shown and appendix). This difference in the ability of Δggt mutant strains to 
colonize adults versus their inability to settle in the juvenile stomach implies that GGT is 
crucial for initial colonization in early, neonatal infections and later on acts as a 
tolerance-promoting immunomodulator of the adult immune system. 
The details of how VacA and GGT prevent DC maturation and promote DC tolerization 
need to be clarified yet.  Most likely both factors act via entirely different mechanisms. In 
addition to the already mentioned effects of VacA on DC maturation, this virulence factor 
has been described to prevent autophagy in epithelial cells (224) and to interfere with 
phagosome maturation in macrophages (225). If VacA acts in the same manner on DCs, 
their failure to respond properly to ΔvacA strains could be explained. With regard to the 
involvement of GGT, an explanation is less straight forward. Treatment of neonatally and 
adult mice infected with wild type H. pylori with acivicin, an inhibitor of GGT, either 
prevents colonization (neonatal infection) or reduces the bacterial burden (adult 
infection), suggesting that the effects depend on the enzymatic activity of GGT rather 
than on the molecule per se. Since GGT catalyzes the transfer of the gamma-glutamyl 
residue of glutathione or glutamine to amino acids or peptides generating cysteines, a 
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possible role of glutathione on DC tolerization can be considered and will be tested by 
supplementation with increasing concentrations of both compounds. 
In conclusion, both bacterial factors VacA and GGT are critically involved in the re-
programming of DCs towards a tolerance-promoting phenotype, thereby enabling initial 
and persistent infection of the host. Identifying such bacterial "tolerance factors" is of 
great importance and their putative beneficial effects on immune homeostasis might be 
used someday to develop either sterilizing and/or tolerizing vaccinations against H. 
pylori.   
 
 
4.5 HELICOBACTER PYLORI-SPECIFIC TOLERANCE AND ASTHMA 
 
As mentioned in section 1.2.3, several epidemiological surveys suggest an inverse 
association between H. pylori infections and asthma, as well as allergic and chronic 
inflammatory diseases (71-74, 215, 226). This correlation is especially evident in children and 
young adults, which are less likely to carry the pathogen (71-73). While infection rates has 
declined from >50% at the beginning of the 20th century to <10% at its end, the 
prevalence of early on-set asthma has increased at an astonishing rate in the same time 
period (226, 227) (Fig 4B). First experimental data to underscore an inverse correlation were 
provided by our lab. Arnold et al. found that neonatal infection with H. pylori protects 
mice against the clinical and histopathological symptoms of asthma, i.e. airway hyper-
responsiveness, tissue inflammation, goblet cell metaplasia, and prevents the infiltration 
of eosinophils, Th2 and Th17 cells into the bronchoalveolar fluid. Asthma protection 
could be transferred from neonatally infected mice to challenged recipients via the 
transfer of relatively small numbers of purified Tregs (70).  
Interestingly, the lungs of neonatally infected mice were infiltrated primarily with semi-
mature DCs, whereas mature DCs constituted the majority of DCs in asthmatic lungs, 
suggesting a causal relationship between tolerance-promoting immune cell populations 
(Tregs and semi-mature DCs) and asthma protection (70). Having observed the 
requirement for DC-derived IL-18 in Treg differentiation in vitro and in vivo, we assumed 
that Tregs from neonatally infected IL-18-/- or IL-18r-/- mice should lack this suppressive 
activity in the model of allergen-induced asthma. Indeed, Tregs isolated from neonatally 
infected wild type mice but not IL-18-/- or IL-18r-/- mice suppressed experimentally 
induced allergic airway disease, highlighting again the importance of IL-18 for Treg 
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differentiation in vivo. Using the same model, we were able to show that mice neonatally 
infected with H. pylori lacking VacA (ΔvacA) are not protected against the clinical and 
histopathological manifestations of disease, again underscoring the importance of VacA 
in the induction of functional, suppressive Tregs (see appendix 7.1). Since the Δggt 
mutant is not able to colonize its hosts in the neonatal period no data on the loss of 
protection in the asthma set-up could be gathered with GGT-deficient strains, but 
preliminary results suggest that intraperitoneal injection of 5μg/g bodyweight purified 
GGT to uninfected neonates over 3 weeks is sufficient to protect from allergen-induced 
asthma (unpublished data). This protective effect of the purified GGT supports the 
necessity for GGT-proficiency to induce H. pylori-specific immune tolerance. In the near  
Fig. 14: Current working model of H. pylori-induced immune tolerance and asthma protection: In 
chronically infected hosts, VacA- and GGT-proficient H. pylori resides in the gastric mucosa where it is 
detected by tissue-resident DCs sampling the gastric lumen. H. pylori-experienced DCs acquire a semi-
mature, tolerogenic phenotype prior to migration to the gut-draining MLN, where they induce CD25+FoxP3+ 
Tregs in an IL18- and TGF-β-dependent manner, but fail to effectively induce H. pylori-specific Th1-/Th17-
responses. Peripherally induced Tregs prevent excessive gastric immunopathology and enable the bacteria 
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to persist in the host by retaining MLN DCs in a semi-mature state and by directly suppressing pathogen-
specific Th1-/Th17-responses. Once induced, Treg migrate to the lungs where they suppress allergen-
specific Th2-/Th17-responses, thereby preventing the pathogenesis of asthma. Prevention of allergic T-cell 
responses is either achieved by suppression of Th2- and Th17-responses by Treg/T-effector contact, 
secretion of soluble cytokines like IL-10, and/or by retaining lung-resident DCs in a semi-mature state.  
Suppression of Th2-/Th17-responses and the inhibition of DC maturation leads to reduced eosinophilia, 
mucus production, goblet cell metaplasia and airway hyper-responsiveness. Adapted from (215). 
 
future it will be of great interest to elucidate receptors (NLR`s, C-type lectins?) and 
signaling pathways (wnt-, β-catenin signaling?) engaged by VacA and GGT in order to 
find the key to the tolerogenic re-programming of DCs by H. pylori. Although the initial 
modulation of the immune system towards tolerogenicity by the induction of semi-mature 
DCs likely takes place in the gastric mucosa, with the subsequent instruction of naive T 
cells to become Tregs in the draining MLNs, asthma protection is most likely not 
achieved by migratory gastric DCs infiltrating the lungs. It is more likely that newly 
induced Tregs migrate into the lungs, where they directly block allergic T cell responses 
by suppressing allergen-induced Th2-/Th17-polarization. The block of T cell responses 
can either be achieved via Treg/T-effector cell contact or via soluble cytokines, in 
particular IL-10. Alternatively, the migrated Tregs retain lung DCs in a semi-mature state, 
thereby preventing the instruction of allergen-specific T-cells and/or inducing FoxP3+ 
Tregs in the tracheal lymph nodes (Fig. 14). 
 
 
4.6. SYNTHESIS 
 
The gram-negative bacterial pathogen H. pylori colonizes the gastric mucosa of one half 
of the world population. The infection is acquired in early childhood and typically persists 
for many decades. Humans and H. pylori have intimately co-existed at least since our 
ancestors first migrated out of East Africa 60000 years ago (228). This long period of co-
existence allowed the bacteria to aquire traits that enable them to evade immune 
surveillance by subverting both innate and adaptive components of the immune system 
to ensure persistence despite a vigorous, yet non sterilizing, local and systemic immune 
response. On the other hand, modulation of the immune system by H. pylori protects 
carriers against asthma and probably other allergic, chronic, inflammatory and 
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autoimmune diseases. The possible loss of fitness due to gastric pathology has been 
proposed to be offset by these protective effects against a variety of diseases. 
The present work delivers some crucial components involved in mediating H. pylori-
specific tolerance and protection against asthma. We were able to identify DCs, a critical 
link between the innate and adaptive branches of the immune system, as a fundamental 
part of this symbiosis. Moreover, we highlighted the necessity for different cytokines, i.e. 
IL-18 and TGF-β, to enable the bacteria to persist in its host and to confer asthma 
protection. Finally, we identified two bacterial factors, namely VacA and GGT, that 
induce tolerogenic DCs. These findings help us to understand the immunomodulatory 
properties of H. pylori and its putative beneficial effects on immune homeostasis, thereby 
opening up new avenues for the prevention of allergies and possible other chronic 
inflammatory diseases of increasing importance in industrialized countries from which H. 
pylori is disappearing. 
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